|
Patent landscape, scope, and claims: |
United States Patent 8,178,693: Scope, Claim Architecture, and Patent Landscape
What is the core claim scope of US 8,178,693?
US 8,178,693 is a “Markush-style” small-molecule patent claiming a broad genus of compounds (claim 1), plus narrower dependent selections, and two composition claims.
Claim 1 defines a compound “of the formula” (the structural formula is not reproduced in the excerpt you provided) with layered substituent definitions across multiple positions identified as R1, R2, R7, R8, R9, A, R3, R4, R5, R6 and additional optional ring-forming relationships. The claim is dominated by three design features:
- Wide substitution freedom per position
- Each of R1, R2, R9 can be independently selected from a long list that includes:
- simple atoms (H, halogen),
- common electronics (cyano, nitro, CF3, OCF2H/OCF3-like motifs),
- linkage motifs (OR3, OC(O)R3, C(O)NR3R4, NR5C(O)NR3R4, etc.),
- thioether/ sulfonamide / sulfone-like motifs (including SO2NR3R4 and related),
- and large diversity of hydrocarbon and heterocycle scaffolds (alkyl/alkenyl/alkynyl/cycloalkyl plus aryl/heteroaryl/heterocyclyl and substituted variants).
- A second-tier variability layer for R3 and attached substituent patterns
- R3 is selected from a similarly broad set and itself carries 1 to five optional substituents on each attached alkyl/aryl/heterocycle unit, drawn from the same substitution menu.
- Position-specific constraints for “A”, “R8”, “R6”, and “R7”
- A is limited to: —OR3 or —NR4OR3
- R8 is limited to a defined set that is narrower than R1/R2/R9, including: SCF3, Cl, Br, F, cyano, nitro, CF3, OCF3, azido, OR3, carbonyl/urethane/amide-like groups, sulfonamide-like groups, alkyl/aryl/heteroaryl/heterocyclyl variants, plus specified sulfoxide-like patterns —S(O)j(...).
- R6 and R7 are also broad but each appears to have its own allowed structural categories and substitution limits.
Claims 2–10 progressively tighten the substituent sets using explicit selections and constraints (examples include “R9 is fluoro”, “R8 is chloro or bromo”, “R1 is methyl or chloro”, cycloalkyl/heterocycloalkyl ranges, and specific A selection).
How do the dependent claims narrow the genus?
The excerpt includes several materially different narrowing strategies:
Claim 2: Explicit tightening of multiple key substituents
Claim 2 adds specific restrictions:
- R7 becomes limited to C1–C10 alkyl or C3–C7 cycloalkyl/cycloalkylalkyl or C3–C7 heterocycloalkyl/heterocycloalkylalkyl, each optionally substituted with 1–3 groups.
- R9 limited to hydrogen or halogen
- R1 limited to C1–C10 alkyl or halogen
- R8 limited to —OCF3, —Cl, —Br, or —F
This is a coordinated narrowing: it locks the “halogen/fluorinated cap” chemistry (R8) while restricting ring size for R7.
Claims 3–7: Sequential hard picks for R9, R1, R8
- Claim 3: R9 is fluoro
- Claim 4: R1 is methyl or chloro
- Claim 5: R8 is chloro or bromo
- Claim 6: R1 is methyl or fluoro
- Claim 7: R8 is chloro or bromo
These claims likely map to preferred embodiments with strong lipophilicity/electronics (fluoro at one position, chloro/bromo at another).
Claim 8: Locks A
Claim 9–10: Another coordinate narrowing package (adds R2=H and R10=H and defines R8 set)
- Claim 9 restricts:
- R7 to the C1–C10 alkyl / C3–C7 cycloalkyl / C3–C7 heterocycloalkyl buckets (and substitution limits remain 1–3),
- R8 to —OCF3, —Br, or —Cl,
- R2 to hydrogen,
- R1 to C1–C10 alkyl or halogen,
- R9 to hydrogen or halogen,
- R10 is hydrogen.
- Claim 10: A is —NR4OR3 (again)
This looks like a second preferred-embodiment family, using:
- an “R10 fixed” element (not present elsewhere in the excerpt),
- R2 forced to H,
- and R8 forced away from fluorine-only selections (it includes OCF3, Br, Cl).
How broad is the compound coverage relative to typical drug patents?
Within the excerpt, claim 1 provides extremely wide genus coverage because it allows:
- multiple positions (R1, R2, R9, R3, R4/R5/R6/R7/A) to vary over:
- small atoms and multiple functional groups,
- multiple carbonyl and sulfonamide motifs,
- and a large menu of aryl/heteroaryl/heterocycle substituents.
- optional substitution counts are stated as:
- “one to five groups” for substituents on R3-embedded substituent-bearing units, and
- “one to three groups” for the ring options created by R′/R″ pairing or R4/R5 ring-forming (where ring closure occurs).
Net effect: the claim reads like a structure class with a large chemical neighborhood around a single scaffold framework. In freedom-to-operate terms, this increases the chance that design-around candidates still fall inside the literal scope unless they break one of the hard constraints that occur in dependent claims (for example, R8 limited to OCF3/Cl/Br/F, or R9 fixed to fluoro, or A fixed to NR4OR3).
What is the structure of claim 11–14 (compositions)?
- Claim 13: “A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.”
- Claim 14: “A composition comprising a compound of claim 11 and a pharmaceutically acceptable carrier.”
Claims 11 and 12 in the excerpt appear truncated (“selected from: and pharmaceutically acceptable salts thereof”), so the exact enumerated species are not visible here. Still, the composition structure is standard:
- one claim covers compositions of the broad genus (claim 1),
- and another covers compositions of a specific set of compounds (claim 11).
What does the claim architecture imply for infringement risk?
Even without the missing core scaffold formula in the excerpt, the claim text indicates infringement risk is governed by whether an accused compound matches the positional identity of:
- which positions are halogen vs hydrogen vs CF3-like vs OCF3,
- whether the substituent at R8 is from the R8 menu (including SCF3 and halogens),
- whether A is exactly —OR3 or —NR4OR3,
- whether ring-forming options are used (the claim allows certain ring closures), which expands literal coverage for bridged analogs.
Because claim 1 includes both:
- direct substituent options and
- options that allow different substituents to be taken together to form rings,
many “scaffold edits” may still land within scope if they preserve the same positional chemistry mapping.
Patent landscape: Where would US 8,178,693 sit in a typical competitor map?
How should this patent be treated in an ANDA/Paragraph IV-style landscape?
A compound-genus patent with broad Markush scope and composition claims typically plays the role of:
- Primary blocking patent for close analogs, because claim 1 covers a wide neighbor set.
- Secondary risk amplifier because composition claims extend coverage to dosage forms and carrier formulations that include a covered compound.
For an ANDA filing, this raises two practical points:
- If a generic applicant’s candidate is structurally close enough to fall within claim 1, the composition claims become a leverage point even when the generic tries to argue differences at the carrier/formulation layer.
- Dependent claims (2–10) create specific “anchor embodiments” that may match known medicinal chemistry series produced by competitors. Even if the applicant avoids the most obvious subset, claim 1 may still capture less obvious variants.
Where do design-around strategies tend to fail against this kind of claim?
Against a claim like this, design-around often fails when:
- the patent is broad in both electronics (CF3/OCF3/halogen/cyano/nitro) and heterocycle substituent variety,
- and the claim does not restrict the scaffold core beyond the positional group definitions.
In practice, unless a competitor changes:
- the mapping of A (switching away from —OR3/—NR4OR3),
- the allowed “R8 identity set” (including halogen/SCF3/OCF3 inclusion),
- or ring-forming constraints,
the product may remain within the genus.
Key takeaways
- US 8,178,693 claim 1 is a highly expansive genus with variability at multiple positions (R1, R2, R3, R6, R7, R8, R9, and A), including wide functional group and substituent menus and explicit ring-forming options.
- Dependent claims 2–10 narrow scope using coordinate fixes (notably R8 restrictions to OCF3/Cl/Br/F sets, R9 fixed to fluoro in claim 3, A fixed to —NR4OR3 in claims 8 and 10, and coordinated constraints like R2=H and R10=H in claim 9).
- Claims 13–14 extend protection to pharmaceutically acceptable carrier compositions, creating formulation-level exposure in addition to molecule-level exposure.
- For landscape mapping, this patent functions as a broad compound-family blocker: it increases the probability that “close analogs” from competitors still land inside literal scope.
FAQs
1) Does claim 1 require a specific biological target or mechanism?
No. The excerpt shows a purely chemical genus definition plus salt and composition elements. It reads as a compound-structure claim, not a target-linked claim.
2) Which variable appears most constrained in the excerpt?
A is highly constrained: —OR3 or —NR4OR3. By contrast, R1/R2/R9 and R3 each have very broad enumerations.
3) What is the role of the ring-forming clauses?
They expand literal coverage by permitting substituent variables to be taken together to form 4 to 10 membered heteroaryl/heterocyclic rings (and in some cases carbocyclic/heteroaryl/heterocyclic rings), while allowing additional optional substituents.
4) Do the composition claims add meaningful incremental risk?
Yes. Claim 13 covers compositions with a covered compound from claim 1 using pharmaceutically acceptable carriers; claim 14 does the same for the species set referenced by claim 11 (as shown in the excerpt, the species list itself is truncated).
5) Which dependent claims likely track preferred medicinal chemistry examples?
Claims that fix key groups are the strongest candidates: claim 3 (R9=fluoro), claim 4–7 (R1 fixed to methyl/halogen and R8 to Cl/Br sets), claim 8 and 10 (A=—NR4OR3), and claim 9 (R2=H and R10=H with R8 limited to OCF3/Br/Cl).
References
[1] United States Patent US 8,178,693. Claims 1–14 (as provided in the prompt excerpt).
More… ↓
⤷ Start Trial
|
